Compare Quest Diagnostics Inc (DGX) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Quest Diagnostics Inc trades at $231.66 (market cap $25.48B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.21 (market cap $17.89B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days on average.
| DGX | HYG | |
|---|---|---|
Market Cap | $25.48B | $17.89B |
Volume | 941,866 | 44,866,592 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $81.28 |
52-Week Low | $173.49 | $76.90 |
Typical Hold Time | 56 Days | 60 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
HYG trades at $77.205, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The ETF maintains regular dividend distributions, with recent payouts ranging from $0.38 to $0.44. Market focus remains on high-yield bond performance amid rising Treasury yields and Federal Reserve policy uncertainty.
The outlook for HYG remains challenged by persistent bond market volatility and rising interest rates. While the fund's consistent dividend payments provide income support, the bearish technical setup and macroeconomic headwinds suggest continued pressure on high-yield corporate bonds. Investors face risks from credit quality deterioration and duration exposure in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
